These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19884519)

  • 21. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
    Collier A; Ghosh S; McGlynn B; Hollins G
    Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
    Whelan P
    Eur Urol; 2008 Oct; 54(4):823-4. PubMed ID: 18243509
    [No Abstract]   [Full Text] [Related]  

  • 23. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
    Ng HS; Koczwara B; Roder D; Vitry A
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer.
    Gupta D; Lee Chuy K; Yang JC; Bates M; Lombardo M; Steingart RM
    J Oncol Pract; 2018 Oct; 14(10):580-587. PubMed ID: 30312560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
    Hu JR; Duncan MS; Morgans AK; Brown JD; Meijers WC; Freiberg MS; Salem JE; Beckman JA; Moslehi JJ
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e55-e64. PubMed ID: 31969015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT?
    Galvão DA; Newton RU; Taaffe DR; Spry N
    Nat Clin Pract Urol; 2008 Jun; 5(6):306-7. PubMed ID: 18431358
    [No Abstract]   [Full Text] [Related]  

  • 27. Don't think once, think twice! the cardiovascular effects of androgen deprivation therapy.
    Jefferies ER; Thurairaja R; Persad RA; Rajani R; Phull JS; Bahl A
    BJU Int; 2011 Apr; 107(7):1023-8. PubMed ID: 21438973
    [No Abstract]   [Full Text] [Related]  

  • 28. The 'flare' phenomenon: should we be concerned?
    Thurairaja R; Persad R; Peters J; Bahl A
    BJU Int; 2005 Jul; 96(1):4-6. PubMed ID: 15963110
    [No Abstract]   [Full Text] [Related]  

  • 29. [Osteoporosis prophylaxis in men? Adverse effects of total androgen blockade in carcinoma of the prostate].
    Hüfner M
    Internist (Berl); 1999 Aug; 40(8):883. PubMed ID: 10476490
    [No Abstract]   [Full Text] [Related]  

  • 30. Long term androgen deprivation therapy in prostate cancer.
    Ockrim JL; Abel PD
    BMJ; 2008 Sep; 337():a1361. PubMed ID: 18809586
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiovascular risks of androgen deprivation therapy.
    Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
    Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen deprivation therapy--managing side effects.
    Kabir S; Mancuso P; Rashid P
    Aust Fam Physician; 2008 Aug; 37(8):641-6. PubMed ID: 18704213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
    Keating NL; O'Malley A; Freedland SJ; Smith MR
    J Natl Cancer Inst; 2012 Oct; 104(19):1518-23. PubMed ID: 23210129
    [No Abstract]   [Full Text] [Related]  

  • 34. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
    Boudreaux KJ; Chang SS
    BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172
    [No Abstract]   [Full Text] [Related]  

  • 35. Androgen deprivation therapy in prostate cancer: looking beyond prostate-specific antigen and testosterone levels.
    Saad F
    Eur Urol; 2015 May; 67(5):837-8. PubMed ID: 25168615
    [No Abstract]   [Full Text] [Related]  

  • 36. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 37. [Androgen deprivation and cardiovascular risk in prostate cancer treatment].
    Leclercq C; Bouchot O; Azzouzi AR; Joly F; Miaadi N; Pfister C; Vincendeau S; de Crevoisier R
    Prog Urol; 2012 Sep; 22 Suppl 2():S48-54. PubMed ID: 23098790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leuprolide causes pure red cell aplasia.
    Maeda H; Arai Y; Aoki Y; Okubo K; Okada T; Ueda Y
    J Urol; 1998 Aug; 160(2):501. PubMed ID: 9679912
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiovascular effects of androgen depletion and replacement therapy.
    Pinthus JH; Trachtenberg J; Klotz L
    Urology; 2006 Jun; 67(6):1126-32. PubMed ID: 16765164
    [No Abstract]   [Full Text] [Related]  

  • 40. Limiting the adverse effects of androgen suppression.
    Prescrire Int; 2013 Jan; 22(134):21. PubMed ID: 23367680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.